Singapore-based investment firm August Global Partners (AGP) has officially announced the final closing of its second healthcare-focused fund, the AGP Healthcare Fund (AGPHC), at US $150 million exceeding its original target of US $100 million.  With this, AGP’s total assets under management across its funds now stand at US $350 million. 

The fund raised fresh capital from a broad base of limited partners including institutional investors, family offices and strategic backers from Asia, Europe and North America  reflecting strong confidence in AGP’s health-tech investment thesis even during uncertain global markets. 

AGP describes its investment mandate under AGPHC as targeted toward “transformative, high-growth opportunities” across healthcare verticals  including digital health, precision medicine, advanced medical-device manufacturing, genomics, med-tech platforms, and next-gen care delivery solutions.  Indeed, the fund has already deployed capital in early deals such as a genomics/diagnostics company in Vietnam, and a med-tech imaging/fluorescence-guided surgery firm preparing for a public listing  signalling the kind of high-impact, cross-border investments AGP intends to champion. 

Founders and partners at AGP said the closing reflects the growing opportunity at the intersection of medical technology, AI-driven healthcare, demographic shifts (aging populations), and rising demand for preventive and precision care across Asia. They promise a disciplined, founder-friendly approach, supporting companies from early growth through scale-up, while addressing critical healthcare challenges like aging, chronic disease, diagnostics access, and advanced therapeutics.